PMID- 31049986
OWN - NLM
STAT- MEDLINE
DCOM- 20191219
LR  - 20191219
IS  - 2042-7158 (Electronic)
IS  - 0022-3573 (Linking)
VI  - 71
IP  - 8
DP  - 2019 Aug
TI  - An overview of active and passive targeting strategies to improve the 
      nanocarriers efficiency to tumour sites.
PG  - 1185-1198
LID - 10.1111/jphp.13098 [doi]
AB  - OBJECTIVES: This review highlights both the physicochemical characteristics of 
      the nanocarriers (NCs) and the physiological features of tumour microenvironment 
      (TME) to outline what strategies undertaken to deliver the molecules of interest 
      specifically to certain lesions. This review discusses these properties 
      describing the convenient choice between passive and active targeting mechanisms 
      with details, illustrated with examples of targeting agents up to preclinical 
      research or clinical advances. KEY FINDINGS: Targeted delivery approaches for 
      anticancers have shown a steep rise over the past few decades. Though many 
      successful preclinical trials, only few passive targeted nanocarriers are 
      approved for clinical use and none of the active targeted nanoparticles. Herein, 
      we review the principles and for both processes and the correlation with the 
      tumour microenvironment. We also focus on the limitation and advantages of each 
      systems regarding laboratory and industrial scale. SUMMARY: The current 
      literature discusses how the NCs and the enhanced permeation and retention effect 
      impact the passive targeting. Whereas the active targeting relies on the 
      ligand-receptor binding, which improves selective accumulation to targeted sites 
      and thus discriminates between the diseased and healthy tissues. The latter could 
      be achieved by targeting the endothelial cells, tumour cells, the acidic 
      environment of cancers and nucleus.
CI  - (c) 2019 Royal Pharmaceutical Society.
FAU - Attia, Mohamed F
AU  - Attia MF
AUID- ORCID: 0000-0002-9413-6552
AD  - CNRS, CAMB, UMR 7199, Universite de Strasbourg, Strasbourg, France.
AD  - Department of Bioengineering, Clemson University, Clemson, SC, USA.
AD  - National Research Centre, Cairo, Egypt.
FAU - Anton, Nicolas
AU  - Anton N
AUID- ORCID: 0000-0002-7047-9657
AD  - CNRS, CAMB, UMR 7199, Universite de Strasbourg, Strasbourg, France.
FAU - Wallyn, Justine
AU  - Wallyn J
AD  - CNRS, CAMB, UMR 7199, Universite de Strasbourg, Strasbourg, France.
FAU - Omran, Ziad
AU  - Omran Z
AD  - Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Umm Al-Qura 
      University, Umm Al-Qura, Kingdom of Saudi Arabia.
FAU - Vandamme, Thierry F
AU  - Vandamme TF
AD  - CNRS, CAMB, UMR 7199, Universite de Strasbourg, Strasbourg, France.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20190503
PL  - England
TA  - J Pharm Pharmacol
JT  - The Journal of pharmacy and pharmacology
JID - 0376363
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Drug Carriers)
SB  - IM
MH  - Animals
MH  - Antineoplastic Agents/*administration & dosage/*chemistry
MH  - Drug Carriers/*chemistry
MH  - Drug Delivery Systems/methods
MH  - Humans
MH  - Nanoparticles/*administration & dosage/*chemistry
MH  - Neoplasms/*drug therapy
MH  - Tumor Microenvironment/drug effects
OTO - NOTNLM
OT  - active and passive drug targeting
OT  - enhanced permeation and retention
OT  - ligand
OT  - nanocarriers
OT  - tumour
EDAT- 2019/05/03 06:00
MHDA- 2019/12/20 06:00
CRDT- 2019/05/04 06:00
PHST- 2018/09/18 00:00 [received]
PHST- 2019/04/07 00:00 [accepted]
PHST- 2019/05/03 06:00 [pubmed]
PHST- 2019/12/20 06:00 [medline]
PHST- 2019/05/04 06:00 [entrez]
AID - 10.1111/jphp.13098 [doi]
PST - ppublish
SO  - J Pharm Pharmacol. 2019 Aug;71(8):1185-1198. doi: 10.1111/jphp.13098. Epub 2019 
      May 3.